Trial · NCT01166958
Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
NCT01166958, Phase 4, Completed, University of Wisconsin, Madison; results first posted 2014-09-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Trials, record NCT01166958. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01166958
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
- NCT number
- NCT01166958
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 26 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Osteoporosis
- Interventions
- Teriparatide, Raloxifene
- First posted
- 2010-07-21
- Last updated
- 2014-09-22
- Results first posted
- 2014-09-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum Markers of Skeletal Turnover (Serum CTX) | These were measured at the baseline and 1, 1.5, 2, 2.5, 3, 4, 5 and 6 month visits. | Serum CTX was measured at all study visits following the screening visit. The outcome data is an overall average and range from all time points. |
| Primary | Serum Markers of Skeletal Turnover (Serum P1NP) | These were measured at the baseline and 1, 1.5, 2, 2.5, 3, 4, 5 and 6 month visits. | Serum P1NP was measured at all study visits following the screening visit. The outcome data is an overall average and range from all time points. |
| Secondary | Average Bone Mineral Density of the Spine at Baseline, 3 Months and 6 Months | BMD measured at the baseline, 3 month, and 6 month visits. | Spine BMD was measured at the baseline, three month and six month visits. The outcome data is an overall average and range from all time points. |
| Secondary | Average Bone Mineral Density of the Proximal Femur (Hip) at Baseline, 3 Months and 6 Months | BMD measured at the baseline, 3 month, and 6 month visits. | Hip BMD was measured at the baseline, three month and six month visits. The outcome data is an overall average and range from all time points. |
| Secondary | Average Bone Mineral Density of the One-third Radius at Baseline, 3 Months and 6 Months | BMD measured at the baseline, 3 month, and 6 month visits. | One-third radius BMD was measured at the baseline, three month and six month visits. The outcome data is an overall average and range from all time points. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Serum Markers of Skeletal Turnover (Serum CTX) | These were measured at the baseline and 1, 1.5, 2, 2.5, 3, 4, 5 and 6 month visits. | ng/mL | MEAN | |
| SECONDARY | Average Bone Mineral Density of the Spine at Baseline, 3 Months and 6 Months | BMD measured at the baseline, 3 month, and 6 month visits. | g/cm2 | MEAN | |
| PRIMARY | Serum Markers of Skeletal Turnover (Serum P1NP) | These were measured at the baseline and 1, 1.5, 2, 2.5, 3, 4, 5 and 6 month visits. | mcg/L | MEAN | |
| SECONDARY | Average Bone Mineral Density of the Proximal Femur (Hip) at Baseline, 3 Months and 6 Months | BMD measured at the baseline, 3 month, and 6 month visits. | g/cm2 | MEAN | |
| SECONDARY | Average Bone Mineral Density of the One-third Radius at Baseline, 3 Months and 6 Months | BMD measured at the baseline, 3 month, and 6 month visits. | g/cm2 | MEAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Serum Markers of Skeletal Turnover (Serum CTX) | Daily Teriparatide (Forteo) | 0.9887 | Full Range 0.5989 to 1.4042 | ng/mL | |
| Serum Markers of Skeletal Turnover (Serum CTX) | Monthly Cycles of Teriparatide Followed by Raloxifene | 0.5445 | Full Range 0.433 to 0.5838 | ng/mL | |
| Average Bone Mineral Density of the Spine at Baseline, 3 Months and 6 Months | Daily Teriparatide (Forteo) | 0.9599 | Full Range 0.819 to 1.192 | g/cm2 | |
| Average Bone Mineral Density of the Spine at Baseline, 3 Months and 6 Months | Monthly Cycles of Teriparatide Followed by Raloxifene | 0.9006 | Full Range 0.718 to 1.094 | g/cm2 | |
| Serum Markers of Skeletal Turnover (Serum P1NP) | Daily Teriparatide (Forteo) | 128.7 | Full Range 61.3 to 177.9 | mcg/L | |
| Serum Markers of Skeletal Turnover (Serum P1NP) | Monthly Cycles of Teriparatide Followed by Raloxifene | 83.8 | Full Range 52.8 to 110.8 | mcg/L | |
| Average Bone Mineral Density of the Proximal Femur (Hip) at Baseline, 3 Months and 6 Months | Daily Teriparatide (Forteo) | 0.7951 | Full Range 0.677 to 0.939 | g/cm2 | |
| Average Bone Mineral Density of the Proximal Femur (Hip) at Baseline, 3 Months and 6 Months | Monthly Cycles of Teriparatide Followed by Raloxifene | 0.7898 | Full Range 0.667 to 0.943 | g/cm2 | |
| Average Bone Mineral Density of the One-third Radius at Baseline, 3 Months and 6 Months | Daily Teriparatide (Forteo) | 0.6858 | Full Range 0.6 to 0.762 | g/cm2 | |
| Average Bone Mineral Density of the One-third Radius at Baseline, 3 Months and 6 Months | Monthly Cycles of Teriparatide Followed by Raloxifene | 0.687 | Full Range 0.461 to 0.87 | g/cm2 |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Daily Teriparatide (Forteo) | 13 | |
| Overall Study | STARTED | Monthly Cycles of Teriparatide Followed by Raloxifene | 13 | |
| Overall Study | COMPLETED | Daily Teriparatide (Forteo) | 12 | |
| Overall Study | COMPLETED | Monthly Cycles of Teriparatide Followed by Raloxifene | 13 | |
| Overall Study | NOT COMPLETED | Daily Teriparatide (Forteo) | 1 | |
| Overall Study | NOT COMPLETED | Monthly Cycles of Teriparatide Followed by Raloxifene | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Daily Teriparatide (Forteo) | ||
| Total, all-cause mortality | Monthly Cycles of Teriparatide Followed by Raloxifene | ||
| Total, other adverse events | Daily Teriparatide (Forteo) | 0 | 13 |
| Total, other adverse events | Monthly Cycles of Teriparatide Followed by Raloxifene | 0 | 13 |
| Total, serious adverse events | Daily Teriparatide (Forteo) | 0 | 13 |
| Total, serious adverse events | Monthly Cycles of Teriparatide Followed by Raloxifene | 0 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Daily Teriparatide (Forteo) vs Monthly Cycles of Teriparatide Followed by Raloxifene: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01166958
GET https://conductscience.org/api/trials/v1/NCT01166958/registered